The first week on ipamorelin and CJC-1295

One of the most common posts in any peptide community runs like this. Someone is two days into an ipamorelin and CJC-1295 blend, has slept 7 to 8 hours straight for two nights after a stretch of broken sleep, woke up clear rather than groggy, and is wondering what the strength and body-composition changes will look like. The sleep may genuinely have been better. The separate question is whether 48 hours is long enough for the vial to be the reason. On the published timelines it is not, and the gap between those timelines and the first-week report is where most peptide disappointment starts.

What has physically happened by day two

Both compounds act on the pituitary, ipamorelin through the growth-hormone secretagogue receptor and CJC-1295 through the growth-hormone-releasing hormone receptor. The growth-hormone pulse itself is fast. The downstream marker anyone would use to check whether the axis has moved is IGF-1, and that runs slower. In the strongest human study of CJC-1295, published in the Journal of Clinical Endocrinology and Metabolism in 2006, a single subcutaneous dose in healthy adults aged 21 to 61 raised mean plasma growth hormone 2 to 10 fold for six days or more and mean IGF-1 by 1.5 to 3 fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days^[1]. After repeat dosing, IGF-1 stayed elevated for up to 28 days^[1].

Two caveats sit on top of that. The study used the version carrying the drug affinity complex, the albumin-binding linker that produces the multi-day profile, and most of what is sold as CJC-1295 without DAC is MOD-GRF(1-29), with a half-life closer to half an hour. Our CJC-1295 page covers that split. The caveat that matters more here is that everything in that study was a blood measurement. Hormone levels are the fastest thing on the axis to move, and even they take days.

Sleep is the hardest thing to judge from the inside

Sleep is usually the first reported effect, and it is also the outcome where self-assessment is least reliable. A pooled analysis of the placebo arms of randomised trials in primary insomnia, published in Sleep in 2020, found a significant placebo response on both objective and subjective sleep measures, and described it as biphasic: an initial phase in which the placebo response climbs, followed by a plateau^[2]. The steep part of that curve is the first days and weeks, exactly the window a two-night report sits in. People taking an inert capsule in a supervised trial report the same kind of improvement.

The measurement problem is worse than that. A 2023 meta-analysis in Annals of Behavioral Medicine pooled 43 randomised trials of cognitive behavioural therapy for insomnia and found that sleep diaries and polysomnography each showed roughly 30 minutes more sleep after treatment, while actigraphy showed roughly 30 minutes less^[3]. Same treatment, same outcome, opposite direction depending on the instrument. If three validated methods disagree about the sign of the effect, a remembered comparison against how you usually sleep will not settle it. A run of unusually bad nights is also, by definition, a departure from your own average, so the nights after it tend to sit closer to that average whatever else you do.

The timescale in studies that measured real outcomes

For body composition there is a useful upper bound, because researchers have given healthy older adults recombinant growth hormone directly rather than trying to coax it out of the pituitary. A systematic review in Annals of Internal Medicine in 2007 pooled 18 study populations covering 220 participants, mean age 69, at an average dose of 14 micrograms per kilogram per day for an average of about 27 weeks. Fat mass fell by 2.1 kg and lean body mass rose by 2.1 kg, body weight did not change, and bone density and serum lipids did not change^[4]. The growth-hormone groups had significantly more soft tissue oedema, joint pain, carpal tunnel syndrome and gynaecomastia, plus more new diabetes and impaired fasting glucose^[4]. The authors concluded that growth hormone "cannot be recommended as an antiaging therapy"^[4].

Read that as the ceiling. Giving the hormone itself, for roughly six months, produced about 2 kg of movement in each direction and left scale weight where it started. A growth-hormone secretagogue works by raising your own growth hormone, so it is not reasonable to expect it to beat the result of administering the hormone directly. Tesamorelin, the one growth-hormone-releasing analogue with a marketing authorisation, makes the same point about timescale. Sold in the United States as Egrifta SV for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, it rests on two 26-week placebo-controlled studies whose primary measure was percent change in visceral adipose tissue on a CT scan at the L4-L5 level^[5]. Six months and a CT scanner to detect the effect of the approved drug in the class, as the tesamorelin regulation notes set out.

What else changed the week you started

Starting a vial is rarely the only thing that changes. An injury that has forced a training layoff is also a week of unusual rest. Injecting something at a fixed time each evening is itself a bedtime routine. Attention to sleep goes up the moment you start watching for an effect on it. None of that is separable from the compound without a control. There is also the supply question: neither ipamorelin nor CJC-1295 holds a marketing authorisation anywhere in the countries we cover, both sit on the WADA Prohibited List under section S2, and without independent testing the identity and concentration of what is in the vial is an assumption.

What would actually count as information

We are not going to publish a first-cycle schedule, and there is no defensible human therapeutic dose to report for either compound. What is worth saying is that the only things on this axis measurable over a realistic timescale are lab values, and the label for the approved analogue in the class shows what supervision looks like: evaluate glucose status before starting, monitor periodically for impaired glucose tolerance or diabetes, monitor IGF-1 during treatment and consider discontinuing on persistent elevation^[5]. Those concerns apply to anything raising growth hormone, and they need a clinician and a lab, not a sleep tracker.

The honest read on two good nights is that they are two good nights. The research puts the earliest clear movement on the axis in days and anything visible in the mirror in months, so the first week is too early to be judging either. The per-compound picture, including regulatory status by country, is on the ipamorelin and CJC-1295 pages. This article is educational and is not medical advice. If you are considering either compound, or already using one, a healthcare professional who knows your history is the right person to review it with.